Nevro Corp. Stock price

Equities

NVRO

US64157F1030

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:01 2024-03-28 pm EDT 5-day change 1st Jan Change
14.44 USD +0.14% Intraday chart for Nevro Corp. +4.26% -32.90%
Sales 2024 * 441M Sales 2025 * 469M Capitalization 525M
Net income 2024 * -95M Net income 2025 * -81M EV / Sales 2024 * 0.91 x
Net cash position 2024 * 125M Net cash position 2025 * 97.38M EV / Sales 2025 * 0.91 x
P/E ratio 2024 *
-5.46 x
P/E ratio 2025 *
-6.57 x
Employees 1,215
Yield 2024 *
-
Yield 2025 *
-
Free-Float 94.29%
More Fundamentals * Assessed data
Dynamic Chart
1 day+6.26%
1 week+1.69%
Current month-0.96%
1 month-4.57%
3 months-35.37%
6 months-24.62%
Current year-32.99%
More quotes
1 week
13.39
Extreme 13.39
14.54
1 month
13.36
Extreme 13.36
15.98
Current year
13.36
Extreme 13.36
21.74
1 year
13.36
Extreme 13.36
39.68
3 years
13.36
Extreme 13.36
182.45
5 years
13.36
Extreme 13.36
188.14
10 years
13.36
Extreme 13.36
188.14
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 23-04-23
Chairman 63 19-03-18
Director of Finance/CFO 57 20-06-14
Members of the board TitleAgeSince
Director/Board Member 67 11-03-16
Director/Board Member 60 19-12-16
Chairman 63 19-03-18
More insiders
Date Price Change Volume
24-03-28 14.44 +0.14% 332 027
24-03-27 14.42 +6.26% 290,896
24-03-26 13.57 -0.73% 269,696
24-03-25 13.67 +0.81% 398,448
24-03-22 13.56 -2.09% 259,497

Delayed Quote Nyse, March 27, 2024 at 04:00 pm EDT

More quotes
Nevro Corp. is a global medical device company. The Company is focused on delivering life-changing solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. The Company has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a versatile range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. The Company's products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, Surpass Surgical Lead and Reduced-size Surpass-C Surgical Lead. The Company is also focused on a minimally invasive treatment option for patients suffering from chronic sacroiliac joint (SI Joint) pain.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
17
Last Close Price
14.42 USD
Average target price
19.4 USD
Spread / Average Target
+34.54%
Consensus
  1. Stock
  2. Equities
  3. Stock Nevro Corp. - Nyse